Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Prashant Jadav

Internal Medicine Reno, NV Doctor of Osteopathy

NPI 1629574959 CMS profile 11258552

6130 Plumas St, Reno, NV 89519

Open in the dashboard

General payments

$4,614

222 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Prashant Jadav of Reno, NV is reported in the CMS Open Payments database as having received $4,614 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $888 47
2024 General $1,894 102
2023 General $963 41
2022 General $870 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Prashant Jadav
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Prashant Jadav were reported at $888. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Prashant Jadav Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $870 $141 $42–$496 $149
2023 $963 $149 $45–$519 $160
2024 $1,894 $154 $47–$537 $164
2025 $888 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,137 54 payments
  2. Janssen Biotech, Inc. $893 62 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $577 28 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $504 26 payments
  5. Ardelyx, Inc. $435 17 payments
  6. Regeneron Healthcare Solutions, Inc. $305 9 payments
  7. Madrigal Pharmaceuticals $205 4 payments
  8. Intercept Pharmaceuticals, Inc. $147 8 payments
  9. Genzyme Corporation $113 3 payments
  10. Gilead Sciences, Inc. $106 2 payments
  11. Other $192 9 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,317 219 payments
  2. Education $297 3 payments
Products named General payments · program years 2022–2025
  1. STELARA $584 36 payments
  2. ENTYVIO $522 25 payments
  3. SKYRIZI $511 24 payments
  4. RINVOQ $481 21 payments
  5. XIFAXAN $445 23 payments
  6. IBSRELA $435 17 payments
  7. LINZESS $415 25 payments
  8. TREMFYA $310 26 payments
  9. CREON $299 18 payments
  10. DUPIXENT $274 8 payments
  11. Other $1,124 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

48

Median for Student in an Organized Health Care Education/Training Program: 43

Drug cost

$2,836

Median for Student in an Organized Health Care Education/Training Program: $442

Branded share of claims

31.2%

Median for Student in an Organized Health Care Education/Training Program: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 15 $2,549
Pantoprazole Sodium Generic 33 $288

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 30,207 Part D prescribers listed as Student in an Organized Health Care Education/Training Program; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $584
$584 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $191
$191 — —
SKYRIZI
  • AbbVie, Inc. $144
$144 — —
REZDIFFRA
  • Madrigal Pharmaceuticals $135
$135 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $77
  • GENZYME CORPORATION $44
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record